小児科領域におけるCefaclorの基礎的,臨床的検討 (Cefaclor(CCL)<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
Cefaclor, a new orally administrable cephalosporin, was evaluated fundamentally and clinically in children and following results were obtained.<BR>(1) Serum levels of orally administered cefaclor were measured and, revealed a prompt rise and fall with a half life of 20-50 minutes.<BR>Maximal serum level was obtained 30 minutes after administration and was 16.5 μg/ml by a single oral dose of 25 mg/kg of body weight.<BR>Following serum concentrations of cefaclor were one hour, 11.2μg/ml, 2 hours, 2.27μg/ml, 4 hours, 0.77μg/ml and 6 hours, 0.2μg/ml respectively.<BR>(2) Maximal serum concentration was lower than that of cephalexin (CEX). This might be the result of relative unstability of cefaclor compared with CEX.<BR>(3) Clinical evaluation was done in 31 cases, consisting of 18 cases in upper respiratory infection, 8 cases in bronchitis and bronchopneumonia, 3 cases in urinary tract infection and 2 other cases. The results of 29 out of 31 cases were excellent and good clinically.<BR>(4) Among 16 cases, in which pathological microorganisms were isolated from their throat or urine, 14 cases (88%) revealed good responses bacteriologically.<BR>(5) According to these results, it was suggested that cefaclor is more effective on respiratory and urinary tract infections with lesser side effects than CEX is, and useful in pediatric field.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.